KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Short-term Investments (2017 - 2025)

Novartis Ag's Short-term Investments history spans 9 years, with the latest figure at $98.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 94.82% year-over-year to $98.0 million; the TTM value through Dec 2025 reached $98.0 million, down 94.82%, while the annual FY2025 figure was $98.0 million, 94.82% down from the prior year.
  • Short-term Investments for Q4 2025 was $98.0 million at Novartis Ag, down from $1.9 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $15.9 billion in Q4 2021 and bottomed at $98.0 million in Q4 2025.
  • The 5-year median for Short-term Investments is $1.9 billion (2024), against an average of $5.9 billion.
  • The largest annual shift saw Short-term Investments skyrocketed 889.56% in 2021 before it crashed 94.87% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $15.9 billion in 2021, then plummeted by 30.35% to $11.1 billion in 2022, then plummeted by 94.87% to $569.0 million in 2023, then soared by 232.51% to $1.9 billion in 2024, then crashed by 94.82% to $98.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVS's Short-term Investments are $98.0 million (Q4 2025), $1.9 billion (Q4 2024), and $569.0 million (Q4 2023).